Fox Run Management, L.L.C. Tg Therapeutics, Inc. Transaction History

Fox Run Management, L.L.C.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$13.02 - $21.3 $300,254 - $491,199	23,061 Added 83.36%	50,724 $771,000
Q4 2023 Feb 13, 2024	BUY	$6.68 - $18.81 $79,385 - $223,538	11,884 Added 75.32%	27,663 $472,000
Q3 2023 Nov 07, 2023	BUY	$8.36 - $26.5 $131,912 - $418,143	15,779 New	15,779 $131,000
Q1 2023 May 12, 2023	BUY	$10.23 - $19.34 $263,279 - $497,734	25,736 New	25,736 $387,000
Q2 2018 Jul 17, 2018	SELL	$12.5 - $15.0 $209,225 - $251,070	-16,738 Closed	0 $0
Q1 2018 Apr 17, 2018	BUY	$8.7 - $16.8 $145,620 - $281,198	16,738 New	16,738 $238,000

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.